Abstract

DRUGS IN THE TREATMENT OF COVID-19

Ancha Divya*, Sana Fathima, Khoday Namratha and Saleha Fatima

ABSTRACT

COVID-19 is a disease caused by a novel corona virus now referred to as severe acute respiratory syndrome corona virus 2 (SARS-CoV-2; formerly referred to as 2019-nCoV), which was first detected in Wuhan City, Hubei Province, China, during an outbreak of respiratory disease cases. Corona viruses, from peacocks to whales, refer to a family of animal-influencing viruses. They are identified by the bulbtipped spikes that extend from the surface of the virus, giving them the resemblance of a corona. In order to respond to the ongoing serious acute respiratory syndrome corona virus 2 pandemic, treatment interventions for 2019 corona virus disease are urgently needed. In the management of corona virus disease in 2019, both antiviral drugs and immunomodulators could have their role. Unfortunately, no drugs for treating infections with human corona viruses have yet been approved. Since it will take years to produce new therapies for extreme acute respiratory corona virus 2 syndrome, the main emphasis is on modifying drugs that have been accepted or are being developed for several other indications. The data and/or recommendations are divided into 4 classes: (a) anti-viral and anti-inflammatory medicinal products, (b) anti-malaria medicinal products, (c) traditional Chinese medicinal products and (d) other medicinal products.[1]

Keywords: Corona virus, respiratory disease, animal influencing virus, immunomodulators.